| |
Large-scale. Long-term. Maintenance studies in major depressive disorder are broad in scope, duration, and size. Build your optimal study plan and mitigate risk with the help of our guide. Learn more. .png)
|
|
Today’s Big NewsOct 10, 2024 |
|
The deal will help Jubilant Biosys expand its footprints in Europe for drug discovery and pre-clinical offerings in areas like biologics and ADC on top of existing integrated drug discovery services & CDMO from India. 
|
|
| By James Waldron Gritstone bio may have left no stone unturned when it came to searching for a financial rescue, but the vaccine biotech has decided that all roads now lead to bankruptcy. |
|
|
|
By Nick Paul Taylor Ono Pharmaceutical has bought a seat in a quiet corner of the congested antibody-drug conjugate (ADC) space, agreeing to pay LigaChem Biosciences up to $700 million for a potential first-in-class solid tumor candidate LCB97. |
By James Waldron Booster Therapeutics has launched with $15 million in seed financing and a mission to take on the current crop of targeted protein degraders. |
By Nick Paul Taylor Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of its melanoma cell therapy IMA203 this year in light of the response and progression-free survival results seen in a phase 1b study. |
|
When the world is changing, you need a global CDMO with a strong global presence to protect your molecule. Our team of experts help progress any molecule type, however complex, from pre-clinical to commercial. Learn more about our tech transfer capabilities. 
|
|
By Fraiser Kansteiner Astellas subsidiary Universal Cells is establishing a second location overseas at the Japanese pharma’s research campus in Tsukuba. As part of the move, 24 roles held by Universal Cell employees in Seattle are being eliminated. However, 12 of the former Seattle-based roles will be transferred to and filled by employees at the Tsukuba site in Japan. |
By Darren Incorvaia Though the peak of COVID-19 deaths is thankfully behind us, the virus is still a pernicious public health threat that vexes drugmakers by constantly evolving new variants that can elude existing treatments. |
By Gabrielle Masson Syneos Health has tapped Costa Panagos to take the reins from former CEO Colin Shannon, who will transition to the role of executive chair. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Fraiser Kansteiner Following the recent closure of its manufacturing facility in Marion, North Carolina, from flooding caused by Hurricane Helene, Baxter is providing some clarity on remediation timelines. |
By Conor Hale Illumina bills the MiSeq i100 series as a complete redesign of its original MiSeq sequencer, which made its debut in 2011, saying it can operate four times faster and use room temperature reagents. |
By Kevin Dunleavy GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma’s Fraiser Kansteiner and Arnold & Porter’s Dan Kracov break down the BIOSECURE Act's potential impact on the life sciences industry and what comes next after the House of Representatives' recent vote. |
|
|---|
|
|
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
